National Cancer Institute (NCI) - Recruiting N/A to 21 years. - A Phase I/II Study of ABT-888, an Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG).
National Cancer Institute (NCI) - Recruiting 37 Months to 21 years. - A Phase 1 Study of MK-1775 Concurrent With Local Radiation Therapy for the Treatment of Newly Diagnosed Children With Diffuse Intrinsic Pontine Gliomas.
National Institutes of Health Clinical Center (CC) - Recruiting 18 years to 66 years. - A Phase I/II Study of the Safety and Feasibility of Administering T Cells Expressing Anti-EGFRvIII Chimeric Antigen Receptor to Patients With Malignant Gliomas Expressing EGFRvIII.
Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL; Aldesleukin; Fludarabine; Cyclophosphamide
Sanofi - Recruiting 1 year to 18 years. - A Phase 1/2 Combined Dose Ranging and Randomized, Open-label, Comparative Study of the Efficacy and Safety of Plerixafor in Addition to Standard Regimens for Mobilization of Haematopoietic Stem Cells Into Peripheral Blood, and Subsequent Collection by Apheresis, Versus Standard Mobilization Regimens Alone in Pediatric Patients, Aged 1 to <18 Years, With Solid Tumours Eligible for Autologous Transplants..
M.D. Anderson Cancer Center - Recruiting 18 years or older. - A Prospective Randomized Phase III Trial to Compare Local Control and Neurocognitive Preservation After Initial Treatment With Stereotactic Radiosurgery (SRS) Versus Whole Brain Radiation Therapy (WBRT) for Patients With >3 Brain Metastases From Melanoma.
SRS; WBRT; Cognitive Function Tests; Questionnaires
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma.
Sidney Kimmel Comprehensive Cancer Center - Recruiting 18 years or older. - A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects With Recurrent High-Grade Glioma Undergoing Standard, Repeated Temozolomide Treatment.
mibefradil dihydrochloride; temozolomide; 3'-deoxy-3'-[18F]fluorothymidine; pharmacological study
UNC Lineberger Comprehensive Cancer Center - Recruiting 21 years or older. - A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases.
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Phase II Pilot Trial of Radiation Therapy With Concurrent and Adjuvant Temozolomide, Tamoxifen and Carboplatin (T2C) in the Treatment of Patients With Primary Central Nervous System Malignant Gliomas.
AbbVie - Recruiting 18 years or older. - A Randomized, Double-Blind, Phase 2, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer.
to-BBB technologies B.V. - Recruiting 18 years or older. - An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma..
2B3-101; Trastuzumab; 2B3-101 60 mg/m2 every 4 weeks; 2B3-101 50 mg/m2 every 3 weeks
National Cancer Institute (NCI) - Recruiting 3 years to 21 years. - A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND# 7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas.
M.D. Anderson Cancer Center - Recruiting 18 years or older. - A Phase I lead-in to a 2x2x2 Factorial Trial of Dose Dense Temozolomide, Memantine, Mefloquine, and Metformin As Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme.
Cancer Research UK - Recruiting 18 years to 70 years. - A Cancer Research UK Phase I Trial of Olaparib (AZD2281), an Oral PARP Inhibitor, in Combination With Extended Low-Dose Oral Temozolomide in Patients With Relapsed Glioblastoma.
olaparib; temozolomide; gene expression analysis; protein expression analysis; laboratory biomarker analysis; pharmacological study; diffusion-weighted magnetic resonance imaging; dynamic contrast-enhanced magnetic resonance imaging; therapeutic conventional surgery
Institut Paoli-Calmettes - Recruiting 18 years or older. - Double-blind Randomized Multicenter Phase III Study Evaluation of the Efficacy of Hippocampal Avoidance on the Cognitive Toxicity of Whole-brain Radiation Therapy After Surgical Resection of Single Brain Metastasis of Breast Cancer..
Radiation therapy Brain metastasis in breast cancer
Zhejiang Beta Pharma Inc. - Recruiting 18 years to 75 years. - A Single Center, Open Label, Multicenter Study to Determine the Safety and Efficacy of Icotinib in Combination With Whole Brain Radiation Therapy For NSCLC Patients With Brain Metastases.
OHSU Knight Cancer Institute - Recruiting 18 years to 75 years. - A Phase I/II Study of Patient With Newly Diagnosed Primary Central Nervous System Lymphoma Treated With Methotrexate/BBBD, and Adding Rituximab (an Anti CD-20 Antibody) and Carboplatin, to the Treatment Regimen.
Rockefeller University - Recruiting 18 years or older. - A Phase I Study of Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells (DC/AAT) Administered Intradermally to Cancer Patients With Brain Tumors.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase I/Randomized Phase II Trial of Either Dasatinib or Placebo Combined With Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma Multiforme (GBM).
Spectrum Pharmaceuticals, Inc - Recruiting 2 years to 20 years. - Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer.
Guangdong Association of Clinical Trials - Recruiting 18 years to 75 years. - Phase III Study of Icotinib Treat the Patient With Brain Metastasis EGFR-mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy.
National Cancer Institute (NCI) - Recruiting 1 year to 21 years. - A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study
National Cancer Institute (NCI) - Recruiting 18 years or older. - A Prospective Study of Cognitive Function During Chemotherapy for Front-Line Treatment of Ovarian, Primary Peritoneal or Fallopian Tube Cancer.
National Cancer Institute (NCI) - Recruiting 3 years to 30 years. - Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma).
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial..
Samsung Medical Center - Recruiting 18 years or older. - Randomized Phase III Trial of Stereotactic Radiosurgery (SRS) Versus Observation for Patients With Asymptomatic Cerebral Oligo-metastases in Non-small Cell Lung Cancer (NSCLC).
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase II Study, Multicenter, Open-label, Evaluating Efficacy of Treatment With Sutentr (Sunitinib) in Patients With Previously Untreated or Recurrent Brain Metastases Originating From Renal Cancer.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase II Randomized Multicenter Study Comparing Brain Radiation in Combination With Temozolomide or Radiation Alone in Patients With Brain Metastases From Breast Cancer.
Gustave Roussy, Cancer Campus, Grand Paris - Recruiting 6 Months to 20 years. - Phase 2 Single- Arm Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Neuroblastoma and Other Paediatric Solid Tumours.
Gustave Roussy, Cancer Campus, Grand Paris - Recruiting N/A to 10 years. - Treatment Protocol for High-Risk PNET Brain Tumors in Children With Surgery, Sequential Chemotherapy, Conventional and High-Dose With Peripheral Blood Stem Cell Transplantation and Radiation Therapy.